대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	The Role of Sacubitril/Valsartan on Renal Function Among Heart Failure Patient with Concurent Renal Impairment : A Literature Review
저자	Teguh Sulistiyanto, Fajar Alfa Saputra
출판정보	2020; 2020(1):
키워드	Sacubitril/Valsartan \| Renal Function \| Heart Failure \| Renal Impairment \| CKD
초록	Since renal dysfunction is a common comorbidity in patients with Heart Failure, We aimed to explain more and summarized the role of novel Sacubitril/Valsartan on renal function among the heart failure patients with concurrent renal impairment. This literature review used PubMed database as the main tool to find studies involving the used of Sacubitril/Valsartan among heart failure patients with concurrent renal impairment focused on renal function. In addition, the references of those studies were investigated for further relevant information. Sacubitril/Valsartan will be absorbed quickly after oral administration. Almost all sacubitril will be changed in its active form (sacubitrilate) which is then excreted mainly in the urine while valsartan will be excreted mainly through feces. In a study conducted in heart failure patients with reduced ejection fraction co-existing with CKD who received Sac/Val therapy showed a significant improvement in eGFR. Other studies state that the safety of this drug combination can be maintained even in patients with CKD. This maintained kidney function is believed to be a direct effect due to the inhibition of neprylisin and angiotensin II by a combination of these drugs. This inhibition has a renoprotective effect on the kidneys through antioxidant, anti-inflammatory, and antifibrotic effects. In addition, the inhibition of angiotensin II which causes inhibits in the efferent arteriolar vasoconstriction process as compensation to the renal hipoperfusion in heart failure patient is offset by the vasodilation effect of natriuretic peptides system that making intraglomerular pressure can be maintained, so does the GFR. Sacubitril/Valsartan treatment in HF patients with concurent renal impairment has so far shown a good results by preserving kidney function. Besides, this drug is well tolerated even with CKD comorbidities.
원문(PDF)	PDF 원문보기

목록

위로가기